Abstract 2200P
Background
Mediastinal neoplasms are typical but uncommon thoracic diseases with increasing incidence and unfavorable prognoses. A comprehensive understanding of their spatiotemporal distribution is essential for accurate diagnosis and timely treatment. However, previous studies are limited in scale and data coverage. Therefore, we delineate the distribution of mediastinal lesions within a substantial, nationwide, multi-institutional cohort, thereby providing valuable insights into this disease.
Methods
In this multi-center, hospital-based, observational study, we included 20 hospitals from 11 provinces in China. At each institution, a standardized retrospective search of electronic medical records between Jan. 1st, 2009 and Dec. 31st, 2020 was performed. We collected information on sociodemographic characteristics, CT images, and pathologic diagnoses. The incidence of mediastinal neoplasms was analyzed in terms of age, sex, time, compartment, and geographical region.
Results
Among 7,829 cases, the most common mediastinal lesions were thymomas (30.6%), benign mediastinal cysts (23.3%), and neurogenic tumors (10.0%). The distribution of these lesions varied significantly among mediastinal compartments, with thymomas (39.6%), benign cysts (28.0%), and neurogenic tumors (51.7%) being the most commonly observed lesions in the prevascular, visceral, and paravertebral mediastinum, respectively (P < 0.001). The occurrence of mediastinal lesions varied by age, with germ cell tumors being more frequently observed in patients younger than 18 and those aged 18-29 years, whereas thymomas occurred more often in patients over 30 (P < 0.001). Also, the lesion location was associated with age, with patients having paravertebral lesions being the youngest (P < 0.001). Spatial distribution analysis revealed that thymomas were the most common mediastinal lesions across different geographical regions.
Conclusions
This study revealed significant heterogeneity in the spatiotemporal distribution of mediastinal neoplasms. These findings provide useful demographic data when considering the differential diagnosis of mediastinal lesions, and would be beneficial for tailoring disease prevention and control strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2172P - Development and evaluation of the usefulness of an immune-related adverse events interview application
Presenter: AKIKO YANO
Session: Poster session 07
2173P - Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital
Presenter: Niamh Cunningham
Session: Poster session 07
2174P - The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Poster session 07
2175P - Sex and age-related differences in immunotherapy-induced toxicities
Presenter: Mafalda Teixeira da Costa
Session: Poster session 07
2176P - Rechallenge of immune checkpoint inhibitors after immune-related adverse events: A systematic review
Presenter: Jin Young Kim
Session: Poster session 07
2177P - Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
Presenter: Catarina Fernandes
Session: Poster session 07
2179P - Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2180P - Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients
Presenter: Víctor Albarrán
Session: Poster session 07
2181P - Effect of different corticosteroid treatment strategies on checkpoint inhibitors pneumonitis outcomes
Presenter: Hui Guo
Session: Poster session 07
2182P - Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07